Feb 16, 2021 4:05pm EST iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update
Feb 09, 2021 4:30pm EST iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021
Dec 01, 2020 4:30pm EST iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
Nov 24, 2020 7:30am EST iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis
